Biological activity of thymopentin in cutaneous T-cell lymphoma (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Biological activity of thymopentin in cutaneous T-cell lymphoma (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1416 1994. Unique Identifier : AIDSLINE ICDB/95603102
Foss F; Sznol M; Urba W; Kopp W; Duffy P; McCaffrey R; Hesketh P; Longo D; Section of Medical Oncology, Boston University Medical Center,; Boston MA 02118

Abstract: Thymopentin (TP5), a synthetic pentapeptide corresponding to the active site of the human thymic hormone, thymopoietin, has demonstrated immunomodulatory activity in autoimmune diseases, immune deficiencies, and HIV infection. A recent study reported a 75% response rate to TP5 in patients with the Sezary syndrome who had low numbers (less than 2600/mm3) of circulating Sezary cells. We further explored the clinical and biological activity of TP5 in heavily pretreated patients with advanced cutaneous T-cell lymphoma (CTCL) with and without the Sezary syndrome. All patients received 50 mg of TP5 by intravenous infusion three times a week until progression. Of 16 treated patients, 15 had failed prior chemotherapy; 8 had Sezary syndrome, 2 had erythroderma without Sezary cells, and 6 had plaques or tumors. One patient with ulcerated plaques had a partial response with healing of skin lesions, and 7 patients experienced minor response (6 in skin, 1 in nodes) or symptomatic improvement of pruritus. We conclude that TP5 has bioactivity in CTCL and we are currently studying the effects of TP5 on antigen expression on Sezary cells and its immunomodulatory effects on normal lymphoid subsets.

Keywords: Dose-Response Relationship, Drug Drug Administration Schedule Human Immunocompetence/DRUG EFFECTS Infusions, Intravenous Lymphoma, T-Cell, Cutaneous/IMMUNOLOGY/*THERAPY Sezary Syndrome/IMMUNOLOGY/*THERAPY Skin Neoplasms/IMMUNOLOGY/*THERAPY Thymopentin/*THERAPEUTIC USE ABSTRACT
950228
M9521051

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .